1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Global Cystic Fibrosis Market Report -2028

Global Cystic Fibrosis Market Report -2028

  • March 2018
  • 82 pages
  • ID: 5438928
  • Format: PDF
  • EffeMarket

Summary

Table of Contents

Search Inside

Cystic Fibrosis (CF) is a rare genetic disorder caused by a mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene located on chromosome 7. This disorder primarily affects the lungs and digestive system and causes secretions to become thick and sticky. Individuals with Cystic Fibrosis develop lung disease resulting from a cycle of mucus retention, infection, and inflammation, as well as pancreatic dysfunction resulting in calorie malabsorption. The sweat glands and reproductive organs are also affected. The sequence of the CFTR gene was identified in 1989 and it encodes a 1480 amino acid protein. There are approximately 250 known disease-causing mutations that intervene with various stages of CFTR synthesis and function. Every year, approximately 70,000 to 100,000 children and young adults are affected with CF across the world.

The Cystic Fibrosis market is primarily driven by increasing CF prevalence, the rise in R&D expenditure by pharmaceutical companies and increase in funding by government bodies. The rise in the prevalence of Cystic Fibrosis is further attributed to reduced mortality rate due to treatment advancements and better disease management. Drugs such as Orkambi, Kalydeco, Symdeko etc. are expected to boost the market growth, while factors such as the high cost of treatment, and limited availability of medicine for all mutation type’s patients are expected to hamper market growth.

Key players in the Cystic Fibrosis market are Vertex Pharmaceuticals, Roche, Allergan, Novartis, AbbVie, Pharmaxis, Chiesi Farmaceutici, PARI Medical Holding and Gilead Sciences. Vertex Pharmaceuticals is the leading player in the market. The global Cystic Fibrosis market is expected to witness substantial growth during the forecast period. The market is anticipated to reach a value of $12.2 billion by 2028 from the estimated value of $3.8 billion in 2018, at a CAGR of 12.3 percent. This can be attributed to the great investment by market players and many non-profit organizations in the research and development of Cystic Fibrosis therapy. Another factor is the growing penetration of drugs including CFTR modulators during the forecast period and the existence of a strong pipeline.

The Cystic Fibrosis pipeline is comprised of diverse sets of molecules with a majority of products in early-stage development. In total, 124 molecules are in development either alone or in combination with other molecules. The majority of these molecules are in the pre-clinical development stage followed by Phase II and Phase I. Earlier, CF treatment was largely focused on the downstream effects of CFTR dysfunction (mucus retention, infection, and inflammation of the airways) and there have been many advancements in the treatment of those problems. However, new therapies such as CFTR modulators are able to address the underlying abnormalities of Cystic Fibrosis rather than its downstream effects. The effectiveness of these treatments has been established recently. Currently, there are just three FDA-approved molecules targeting specific mutation types that are commercially available in the market.

The majority of companies are focused on the modulators of the CFTR gene, followed by anti-infectives. The Cystic Fibrosis drug market is very competitive and many small players are researching and developing products in this field. Vertex Pharmaceuticals, Galapagos, Flatley Discovery Lab, Ockham Biotech, Proteostasis Therapeutics and Druggability Technologies Holdings are leading the research space.

Key questions answered and insights delivered in the report:
1. Global Cystic Fibrosis market size by value from 2016 to 2028
2. Global Cystic Fibrosis market size by product sales; 2016 and 2017
3. Global Cystic Fibrosis market by therapeutic approach; 2017
4. Comprehensive product landscape by therapeutic class, company, originator, approval date, pharma class, molecule type, mutation type and therapy type
5. Pipeline analysis by stage of development, therapeutic class, molecule type, therapy type, route of administration and company
6. Merger and acquisition, and collaboration by the key players in the market
7. Growth drivers, future opportunities and challenges in the market
8. Earliest priority country filing trend in Cystic Fibrosis market; 2007-2018
9. Cystic Fibrosis patent trend by focus area, route of administration and composition; 2007-2018
10. Cystic Fibrosis patent trend by key patent holder; 2007-2018
11. Key patents in Cystic Fibrosis market; 2007-2018
12. Top inventors in Cystic Fibrosis market; 2007-2018
13. Detailed company profiling of key market players

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Histamine H4 Receptor - Pipeline Review, H2 2020

  • $ 3500
  • October 2020
  • 48 pages

Histamine H4 Receptor - Pipeline Review, H2 2020 Summary According to the recently published report ’Histamine H4 Receptor - Pipeline Review, H2 2020’; Histamine H4 Receptor (AXOR35 or G Protein ...

  • World
  • Dermatological Condition
  • Eye Disease
  • Industry analysis
  • Surgical Procedures Performed
  • Drug Approval

Company Analysis - Vertex $ 3000 October 2020


ref:plp2018

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on